View Older Stories

Mar 3, 2026 10:51AM Jefferies Reiterates Buy Rating on Roivant Sciences (ROIV) amid Brepocitinib NDA acceptance

Feb 10, 2026 06:52AM Roivant Sciences (ROIV) PT Raised to $33 at H.C. Wainwright

Feb 10, 2026 06:31AM Roivant Sciences (ROIV) PT Raised to $38 at Goldman Sachs

Feb 10, 2026 06:13AM Roivant Sciences (ROIV) PT Raised to $35 at Citi

Feb 9, 2026 05:57AM Roivant Sciences (ROIV) call put ratio 16 to 1 put with a focus on February 23 calls

Feb 6, 2026 07:48AM Roivant Sciences Ltd. (ROIV) Misses Q3 EPS by 7c

Jan 6, 2026 07:37AM Leerink on Roivant Sciences (ROIV): 'We expect brepocitinib’s Ph2 cutaneous sarcoidosis (CS) trial to deliver compelling efficacy in 1H26'

Dec 15, 2025 06:40AM Roivant Sciences (ROIV) PT Raised to $26 at H.C. Wainwright

Dec 15, 2025 06:19AM Roivant Sciences (ROIV) PT Raised to $32 at Leerink Partners

Dec 12, 2025 06:07AM Guggenheim Reiterates Buy Rating on Roivant Sciences (ROIV) Post Investor Day

Dec 11, 2025 07:32AM Roivant advances drug timelines, raises $550 million for pipeline

Nov 14, 2025 04:59AM Roivant Sciences (ROIV) PT Raised to $25 at Guggenheim

Nov 11, 2025 04:49AM Roivant Sciences (ROIV) PT Raised to $29 at Leerink Partners

Nov 10, 2025 03:58PM Roivant Sciences (ROIV) PT Raised to $26 at Citi

Nov 10, 2025 08:04AM Roivant Sciences Ltd. (ROIV) Tops Q2 EPS by 15c

Oct 30, 2025 02:47PM Roivant Sciences (ROIV) call put ratio 12 calls to 1 put with a focus on December 20 and January 16 calls

Oct 3, 2025 04:35PM Roivant Sciences (ROIV) files mixed shelf

Oct 1, 2025 01:20PM Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'

Oct 1, 2025 01:13PM FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'

Sep 30, 2025 02:17AM Goldman Sachs Reiterates Buy Rating on Roivant Sciences (ROIV)

Sep 18, 2025 06:59AM Roivant Sciences (ROIV) PT Raised to $20 at H.C. Wainwright

Sep 17, 2025 04:44PM Roivant Sciences (ROIV) PT Raised to $24 at Goldman Sachs

Sep 17, 2025 04:10PM Roivant Sciences (ROIV) PT Raised to $22 at Leerink Partners

Sep 17, 2025 03:36PM Roivant Sciences (ROIV) PT Raised to $16.50 at BofA Securities

Sep 17, 2025 12:33PM Roivant Sciences (ROIV) PT Raised to $21 at Guggenheim

Sep 10, 2025 01:44PM TD Cowen on Roivant Sciences (ROIV): 'We are overall very encouraged by this given importance of the molar ratio patents to ABUS' case'

Sep 4, 2025 07:02AM Pulmovant receives orphan drug status in Japan for lung disease treatment

Sep 2, 2025 09:28AM TD Cowen on Roivant Sciences (ROIV): 'We Like the Risk/Reward Profile of the Stock'

Aug 12, 2025 06:27AM Roivant Sciences (ROIV) PT Raised to $18 at Leerink Partners

Aug 11, 2025 07:08AM Roivant Sciences Ltd. (ROIV) Misses Q1 EPS by 8c

Jul 25, 2025 07:46AM Cantor Fitzgerald Reiterates Overweight Rating on Roivant Sciences (ROIV)

Jul 21, 2025 05:21AM Roivant Sciences (ROIV) call put ratio 2 calls to 1 put on active option volume of 22K contracts

Jul 10, 2025 06:26AM Goldman Sachs Resumes Roivant Sciences (ROIV) at Buy

Jun 25, 2025 08:50AM Roivant Sciences authorizes $500 million share repurchase program

Jun 18, 2025 07:10AM Cantor Fitzgerald Reiterates Overweight Rating on Roivant Sciences (ROIV)

Jun 18, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Roivant Sciences (ROIV)

Jun 18, 2025 06:08AM Guggenheim Reiterates Buy Rating on Roivant Sciences (ROIV)

Jun 16, 2025 07:01AM Roivant Sciences (ROIV) Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

May 28, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Roivant Sciences (ROIV)

Apr 22, 2025 07:04AM H.C. Wainwright Reiterates Buy Rating on Roivant Sciences (ROIV)

Apr 21, 2025 11:03AM Cantor Fitzgerald Reiterates Overweight Rating on Roivant Sciences (ROIV)

Apr 21, 2025 07:02AM Immunovant (IMVT) Announces Leadership Changes

Mar 19, 2025 07:45AM Roivant Sciences (ROIV) Announces Positive Results for Batoclimab Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy Studies

Mar 3, 2025 09:15AM Genevant Sciences (ROIV) and Arbutus Biopharma (ABUS) Initiate International Patent Infringement Enforcement Actions Against Moderna

Feb 10, 2025 07:24AM Roivant Sciences Ltd. (ROIV) Tops Q3 EPS by 48c

Jan 17, 2025 03:31PM Roivant Sciences (ROIV) 30K contracts of January 15 2026 calls

Jan 13, 2025 05:32AM Increasing unusual option volume: EIX INVZ ROIV PCG CHAU NVT SENS OPFI GRRR HPP

Jan 10, 2025 03:43PM Roivant Sciences (ROIV) spreader of 15K contracts of February 10 puts and February 11 calls

Nov 30, 2024 10:00PM JPMorgan is out with its 2025 outlook for biotech stocks

Nov 12, 2024 04:26PM Roivant Sciences Ltd. (ROIV) Misses Q2 EPS by 2c

View Older Stories